The ongoing dispute between the Marshall County Commission and the Personnel Board over a controversial hire could end up in ...

There's an adventure maze not far from the away that is bracing itself for a very busy few weeks as schools break for half ...

A software developer has enhanced an online platform to help parents make more personalized decisions about vaccines for ...

According to the prospectus, the company had raised $536.4 million prior to the IPO, most recently a $215 million Series B round announced this past November. Arch Venture Partners is the largest ...

(RTTNews) - Maze Therapeutics, Inc., (MAZE), a clinical ... The company has initiated a Phase 2 trial of MZE829 in November 2024 and expects to dose its first patient in the first quarter of ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. While Metsera is offering ...

That’s the type of home they need: spacious with a reasonable outdoor area. Maze and Miffy need a home. These two are seriously friendly. They don’t love being handled, but they want to be where their ...

Maze's lead drug in November entered Phase 2 testing for a type of kidney disease caused by mutations in a gene called APOL1. Maze expects to report data in 2026 and, in its IPO filing, claimed the ...

Rabbi Maze and the Jewish Relief Committee sent telegrams of condolence. The Hadimah bore a banner in the funeral procession on which were inscribed the Hebrew words “You Freed Nations And Will ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...

Maze seeks as much as $133 mln in New York IPO Backers include Alphabet's GV and Third Rock Ventures Biotech IPOs set for ramp up in coming weeks Jan 27 (Reuters) - Drug developer Maze ...